AZD9291 + MEDI4736
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic EGFR T790M+ NSCLC
Conditions
Locally Advanced or Metastatic EGFR T790M+ NSCLC
Trial Timeline
Jul 15, 2015 → Jun 21, 2023
NCT ID
NCT02454933About AZD9291 + MEDI4736
AZD9291 + MEDI4736 is a phase 3 stage product being developed by AstraZeneca for Locally Advanced or Metastatic EGFR T790M+ NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT02454933. Target conditions include Locally Advanced or Metastatic EGFR T790M+ NSCLC.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02454933 | Phase 3 | Completed |
Competing Products
20 competing products in Locally Advanced or Metastatic EGFR T790M+ NSCLC